Paul L. Hallenbeck
Founder at Seneca Therapeutics, Inc.
Profile
Paul L.
Hallenbeck was the founder of Synbody Biotechnology, Inc. (founded in 2010) where he held the title of President & Director in 2012.
He was also the founder of Neotropix, Inc. (founded in 2003) where he served as President & Chief Executive Officer in 2011.
Dr. Hallenbeck has worked as a Member-Research Board at Novartis Corp.
and as President at Nisco International Ltd.
In terms of education, Dr. Hallenbeck completed his undergraduate degree at Siena College and pursued graduate and doctorate degrees at the University of Illinois.
Dr. Hallenbeck is also the founder of Seneca Therapeutics, Inc...
Paul L. Hallenbeck active positions
| Companies | Position | Start |
|---|---|---|
Seneca Therapeutics, Inc.
 Seneca Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Seneca Therapeutics, Inc. operates as a biotechnology company. It develops novel oncolytic immunotherapeutics and derivatives as cancer therapeutics, cancer vaccines, and vaccines for the treatment of cancer. The company was founded by Paul L. Hallenbeck and is headquartered in Blue Bell, PA. | Founder | - |
Former positions of Paul L. Hallenbeck
| Companies | Position | End |
|---|---|---|
Synbody Biotechnology, Inc.
 Synbody Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Synbody Biotechnology, Inc. operates as a platform for the discovery and development of novel and attractive molecules. The company was founded by Paul L. Hallenbeck, Chris Diehnelt, Kevin D. Burroughs and Stephen Albert Johnston in 2010 and is headquartered in Chester Springs, PA. | Founder | 2012-12-31 |
| Nisco International Ltd. | President | - |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Neotropix, Inc.
 Neotropix, Inc. BiotechnologyHealth Technology Neotropix, Inc. develops virus-based therapies for cancer treatment. It has developed NTX-010 virus, a small cell lung cancer treatment and as a treatment of pediatric cancers, such as neuroblastoma. The company was founded by Paul L. Hallenbeck in 2003 and is headquartered in Malvern, PA. | Founder | - |
Training of Paul L. Hallenbeck
| Siena College | Undergraduate Degree |
| University of Illinois | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Neotropix, Inc.
Neotropix, Inc. BiotechnologyHealth Technology Neotropix, Inc. develops virus-based therapies for cancer treatment. It has developed NTX-010 virus, a small cell lung cancer treatment and as a treatment of pediatric cancers, such as neuroblastoma. The company was founded by Paul L. Hallenbeck in 2003 and is headquartered in Malvern, PA. | Health Technology |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
Synbody Biotechnology, Inc.
Synbody Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Synbody Biotechnology, Inc. operates as a platform for the discovery and development of novel and attractive molecules. The company was founded by Paul L. Hallenbeck, Chris Diehnelt, Kevin D. Burroughs and Stephen Albert Johnston in 2010 and is headquartered in Chester Springs, PA. | Health Technology |
Seneca Therapeutics, Inc.
Seneca Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Seneca Therapeutics, Inc. operates as a biotechnology company. It develops novel oncolytic immunotherapeutics and derivatives as cancer therapeutics, cancer vaccines, and vaccines for the treatment of cancer. The company was founded by Paul L. Hallenbeck and is headquartered in Blue Bell, PA. | Commercial Services |
| Nisco International Ltd. |
- Stock Market
- Insiders
- Paul L. Hallenbeck
